FDA: Seeks Expedited IND Pilot Applications by 2026

• The FDA has launched its Expedited Investigational New Drug (IND) Pilot to accelerate first-in-human clinical trials.
• The program aims to partner drug companies with Qualified Research Institutions (QRIs) to streamline IND application development.
• Applications for the pilot will be accepted until October 30, 2026.
• A key feature is a rolling review process for IND application components during the pre-IND phase, reducing potential delays.
• The pilot is part of the Trump Administration's Operation TrialBlazer, seeking to maintain U.S. leadership in medical innovation.

The U.S. Food and Drug Administration (FDA) has unveiled the final structure of its Expedited Investigational New Drug (IND) Pilot, a significant initiative designed to dramatically shorten the timeline for bringing new therapies to patients.

The U.S. Food and Drug Administration (FDA) has unveiled the final structure of its Expedited Investigational New Drug (IND) Pilot, a significant initiative designed to dramatically shorten the timeline for bringing new therapies to patients. This program, officially known as the Expedited Investigational New Drug Pilot, aims to accelerate the critical period from initial drug discovery to the commencement of first-in-human clinical trials. A central tenet of the pilot involves fostering collaborations between pharmaceutical companies and Qualified Research Institutions (QRIs), leveraging the latter's specialized scientific knowledge to streamline the development of IND applications.

The FDA is actively seeking participation, with a deadline of October 30, 2026, for submitting FDA Expedited IND Pilot applications. This initiative directly addresses concerns that first-in-human clinical trials in the United States can currently extend up to two years, a pace considerably slower than similar trials conducted in nations like China and Australia. Such delays have been identified as a potential threat to America's standing in global scientific innovation.

The establishment of this FDA IND acceleration program is a direct response to a directive from the Trump Administration, which prioritizes maintaining American leadership in medical innovation by reducing regulatory obstacles and speeding up clinical trial timelines. It forms a key component of broader healthcare modernization efforts undertaken by the administration and is integrated into the U.S. Department of Health and Human Services’ Operation TrialBlazer. This overarching commitment underscores the FDA's proactive stance in tackling challenges within clinical development through targeted programs.

Acting FDA Commissioner Kyle Diamantas, J.D., underscored the dual benefit of the pilot, noting it not only connects industry innovators with leading research institutions to enhance the quality of data submitted to the FDA but also evaluates how these partnerships can expedite processes once clinical trials receive FDA approval. He emphasized that a core priority for the Trump Administration is to stimulate domestic innovation and ensure American patients are among the first to access groundbreaking treatments. Diamantas affirmed the FDA's ongoing dedication to implementing Operation TrialBlazer, aiming to modernize regulatory procedures to keep the nation competitive globally, all while upholding patient safety standards.

The operational design of the Expedited Investigational New Drug Pilot centers on leveraging the substantial scientific expertise of selected Qualified Research Institutions in preparing IND applications. These institutions will enable a unique "rolling review" process, where the FDA can evaluate and accept individual components of an IND application during the pre-IND phase, rather than waiting for the complete submission. This innovative approach is designed to facilitate the identification and resolution of potential issues with an IND application much earlier in the process.

By addressing concerns in real-time, the pilot aims to significantly reduce the likelihood of the FDA placing a first-in-human clinical trial protocol on hold during the standard 30-day IND review period, thereby preventing delays. Karim Mikhail, B. Pharm., M.S., Director of the Center for Biologics Evaluation and Research (CBER), highlighted the program's ambition to harness the American innovation ecosystem to accelerate the timeline for first-in-human clinical trials, which are crucial for establishing proper dosing, absorption, and other vital factors for a drug's potential approval in humans. He reiterated the FDA's commitment to ensuring American patients receive early access to therapies while fostering scientific innovation and investment domestically. The overall goal is to make the journey from scientific discovery to a first-in-human trial more rapid, predictable, and collaborative.

Beyond its immediate impact, the Expedited Investigational New Drug Pilot is designed to generate valuable data that will inform future strategies for modernizing the FDA's support for early-stage clinical development. This evidence could potentially lead to new policy initiatives, including the establishment of a formal accreditation model. Such a model would recognize QRIs that consistently demonstrate robust scientific and regulatory judgment, thereby cultivating a sustainable network of high-quality institutions dedicated to accelerating drug development and the time to first-in-human trials for sponsors.

Furthermore, the pilot actively promotes the coordinated execution of activities that typically run parallel to IND development and review, such as Institutional Review Board (IRB) assessments and the activation of clinical trial sites. By encouraging earlier planning and more synchronized development efforts, the program seeks to eliminate unnecessary delays that can occur between a drug sponsor's initial steps and the commencement of clinical trials.

Lawyers advising pharmaceutical clients or research institutions should inform them about this new pilot program. It offers a significant opportunity to accelerate first-in-human clinical trials through partnerships with Qualified Research Institutions and a rolling review process, potentially providing a competitive advantage for drug development if applications are submitted before the October 30, 2026 deadline.

Source: Original reporting via FDA announcement